Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced their third quarter 2020 financial results.
Recent Corporate Highlights:
“We are pleased with our progress during the quarter and continue to focus on execution and commercialization of our product portfolio. The STEM Animal Health transaction demonstrates the potential global growth of our animal care products and allows Kane Biotech to become a truly global company, giving us access to new markets and revenue. We continue trials in the US and Canada for our human products and the provisional results look very positive and will allow us to grow that segment going forward with a view to returning shareholder value,” stated Marc Edwards President and Chief Executive Officer of Kane Biotech.
Third Quarter 2020 Financial Highlights
Detailed financial information about Kane Biotech can be found in its September 30, 2020 Financial Statements and Management Discussion and Analysis on SEDAR and the Company’s website.
Conference Call Details
Kane Biotech is pleased to invite all interested parties to participate in a conference call on Monday November 30, 2020 at 4.30pm ET during which time the results will be discussed.
Webcast Link: https://edge.media-server.com/mmc/p/ukgs8mo2
Participant Dial In: | ||
Participant Toll-Free Dial-In Number: | (877) 268-9044 | |
Participant International Dial-In Number: | (706) 679-2995 | |
Password: 3572374 | ||
* International dial-ins available at the reservation confirmation attached |
Telco Replay (7 Days valid after the live call) | ||
Toll Free Encore: | 855 859-2056 | |
Toll Encore: | 404 537-3406 | |
Password: 3572374 | ||
A live and archived audio webcast of the conference call will also be available on the investor relations page of Kane Biotech’s corporate website. www.kanebiotech.com
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (52 patents and patents pending, trade secrets and trademarks) and products developed by the Company’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactive+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol “KNE” and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information, please visit www.kanebiotech.com, or contact
Marc Edwards | Ray Dupuis | Graham Farrell |
Chief Executive Officer | Chief Financial Officer | Investor Relations |
Kane Biotech Inc | Kane Biotech Inc | Harbor Access LLC |
medwards@kanebiotech.com | rdupuis@kanebiotech.com | Graham.Farrell@HarborAccessllc.com |
+1 (514) 910-6991 | +1 (204) 298-2200 | +1 (416) 842 9003 |